Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review

References

• SilversteinMDHeitJAMohrDNPettersonTMO’FallonWMMeltonLJ3rdTrends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based studyArch Intern Med199815865855939521222
   PubMed Web of Science ®Google Scholar
• KearonCNatural history of venous thromboembolismCirculation200310723 Suppl 1I22I3012814982
   PubMed Web of Science ®Google Scholar
• SteinPDMattaFMusaniMHDiaczokBSilent pulmonary embolism in patients with deep venous thrombosis: a systematic reviewAm J Med2010123542643120399319
   PubMed Web of Science ®Google Scholar
• BullerHRLensingAWPrinsMHA dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyBlood200811262242224718621928
   PubMed Web of Science ®Google Scholar
• TorbickiAPerrierAKonstantinidesSGuidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Eur Heart J200829182276231518757870
   PubMed Web of Science ®Google Scholar
• AujeskyDPerrierARoyPMValidation of a clinical prognostic model to identify low-risk patients with pulmonary embolismJ Intern Med2007261659760417547715
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAntithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e419Se494S22315268
   PubMed Web of Science ®Google Scholar
• Gómez-OutesASuárez-GeaMLCalvo-RojasGDiscovery of anticoagulant drugs: a historical perspectiveCurr Drug Discov Technol2012928310421838662
   PubMedGoogle Scholar
• CabralKPPharmacology of the new target-specific oral anticoagulantsJ Thromb Thrombolysis201336213314023645472
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyPradaxa^® – Summary of Product Characteristics2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
   Google Scholar
• European Medicines AgencyXarelto^® – Summary of Product Characteristics2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
   Google Scholar
• European Medicines AgencyEliquis^® – Summary of Product Characteristics2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
   Google Scholar
• LipGYAgnelliGEdoxaban: a focused review of its clinical pharmacologyEur Heart J201435281844185524810388
   PubMed Web of Science ®Google Scholar
• MungallDBIBR-1048 Boehringer IngelheimCurr Opin Investig Drugs200236905907
   PubMedGoogle Scholar
• StangierJClinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilateClin Pharmacokinet200847528529518399711
   PubMed Web of Science ®Google Scholar
• TrocónizIFTillmannCLiesenfeldKHSchäferHGStangierJPopulation pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgeryJ Clin Pharmacol200747337138217322149
   PubMed Web of Science ®Google Scholar
• BlechSEbnerTLudwig-SchwellingerEStangierJRothWThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humansDrug Metab Dispos200836238639918006647
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther200578441242116198660
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWDose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurr Med Res Opin200824102757276518715524
   PubMed Web of Science ®Google Scholar
• LangDFreudenbergerCWeinzCIn vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humansDrug Metab Dispos20093751046105519196846
   PubMed Web of Science ®Google Scholar
• WongPCCrainEJXinBApixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJ Thromb Haemost20086582082918315548
   PubMed Web of Science ®Google Scholar
• WangLZhangDRaghavanNIn vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studiesDrug Metab Dispos201038344845819940026
   PubMed Web of Science ®Google Scholar
• RaghavanNFrostCEYuZApixaban metabolism and pharmacokinetics after oral administration to humansDrug Metab Dispos2009371748118832478
   PubMed Web of Science ®Google Scholar
• FurugohriTIsobeKHondaYDU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJ Thromb Haemost2008691542154918624979
   PubMed Web of Science ®Google Scholar
• MorishimaYHondaYKamisatoCComparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in ratsThromb Res2012130351451922647432
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol201050774375320081065
   PubMed Web of Science ®Google Scholar
• BathalaMSMasumotoHOgumaTHeLLowrieCMendellJPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humansDrug Metab Dispos201240122250225522936313
   PubMed Web of Science ®Google Scholar
• MasumotoHYoshigaeYWatanabeKTakakusaHOkazakiOIzumiTIn vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxabanAAPS J201012S2W4308 [abstract]
   Google Scholar
• KawajiHIshiiMTamakiYSasakiKTakagiMEdoxaban for prevention of venous thromboembolism after major orthopedic surgeryOrthop Res Rev201245364
   Google Scholar
• HigginsJPAltmanDGGøtzschePCThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health-care interventions: explanation and elaborationBMJ2009339b270019622552
   PubMed Web of Science ®Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• CochranWGThe combination of estimates from different experimentsBiometrics1954101101129
   Web of Science ®Google Scholar
• HigginsJPTThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKGoldhaberSZTreatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisCirculation2014129776477224344086
   PubMed Web of Science ®Google Scholar
• EINSTEIN InvestigatorsBauersachsRBerkowitzSDOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• EINSTEIN–PE InvestigatorsBüllerHRPrinsMHOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med2012366141287129722449293
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• The Hokusai-VTE InvestigatorsEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKExtended use of dabigatran, warfarin, or placebo in venous thromboembolismN Engl J Med2013368870971823425163
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAApixaban for extended treatment of venous thromboembolismN Engl J Med2013368869970823216615
   PubMed Web of Science ®Google Scholar
• van Gogh InvestigatorsBullerHRCohenATIdraparinux versus standard therapy for venous thromboembolic diseaseN Engl J Med20073571094110417855670
   PubMed Web of Science ®Google Scholar
• van BellenBBamberLCorrea de CarvalhoFPrinsMWangMLensingAWReduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolismCurr Med Res Opin201430582983724432872
   PubMed Web of Science ®Google Scholar
• LiuXJohnsonMMardekianJPhatakHThompsonJCohenAApixaban reduces hospitalizations in patients with VTE: an analysis of the AMPLIFY trialJ Am Coll Cardiol201463Suppl 12A2045 [abstract]
   Google Scholar
• LiuXThompsonJPhatakHMardekianJPorcariARJohnsonMRApixaban reduces hospitalization in patients with venous thromboembolism: An analysis of the AMPLIFY-EXT TrialBlood20131223638 [abstract]
   Web of Science ®Google Scholar
• Gómez-OutesASuárez-GeaMLLecumberriRTerleira-FernándezAIVargas-CastrillónERochaEPotential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patientsVasc Health Risk Manag2013920722823674896
   PubMedGoogle Scholar
• van der HulleTden ExterPLKooimanJvan der HoevenJJHuismanMVKlokFAMeta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolismJ Thromb Haemost2014271116112024819040
   PubMedGoogle Scholar
• FargeDDebourdeauPBeckersMInternational clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerJ Thromb Haemost2013111567023217107
   PubMed Web of Science ®Google Scholar
• LinkinsLADansALMooresLKTreatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e495Se530S22315270
   PubMed Web of Science ®Google Scholar
• KrauelKHackbarthCFürllBGreinacherAHeparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodiesBlood201211951248125522049520
   PubMed Web of Science ®Google Scholar
• WalengaJMPrechelMJeskeWPRivaroxaban – an oral, direct factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopeniaBr J Haematol20081431929918671707
   PubMed Web of Science ®Google Scholar
• WalengaJMPrechelMHoppensteadtDApixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopeniaClin Appl Thromb Hemost201319548248723780399
   PubMed Web of Science ®Google Scholar
• LinkinsLAWarkentinTEPaiMDesign of the rivaroxaban for heparin-induced thrombocytopenia studyJ Thromb Thrombolysis Epub2192014
   PubMed Web of Science ®Google Scholar
• SuryanarayanDSchulmanSPotential antidotes for reversal of old and new oral anticoagulantsThromb Res2014133Suppl 2S158S16624862137
   PubMedGoogle Scholar
• LalibertéFBookhartBKNelsonWWImpact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolismPatient20136321322423857628
   PubMedGoogle Scholar